Regeneron Pharmaceuticals (REGN) Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $18.2 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 3.63% year-over-year to $18.2 billion in Q1 2026; TTM through Mar 2026 was $18.2 billion, a 3.63% increase from a year earlier, with the FY2025 full-year figure at $18.0 billion, down 3.42% from the prior year.
• Current Assets climbed to $18.2 billion in Q1 2026 per REGN's latest filing, from $18.0 billion in the prior quarter.
• Across five years, Current Assets topped out at $19.5 billion in Q4 2023 and bottomed at $14.3 billion in Q1 2022.
• The 5-year median for Current Assets is $18.0 billion (2025), against an average of $17.5 billion.
• Across the five-year window, Current Assets jumped 42.28% in 2022 and dropped 11.65% in 2025, its largest moves.
• Year by year, Current Assets stood at $15.9 billion in 2022, then gained by 22.63% to $19.5 billion in 2023, then slipped by 4.2% to $18.7 billion in 2024, then declined by 3.42% to $18.0 billion in 2025, then rose by 1.04% to $18.2 billion in 2026.
• Per Business Quant, the three latest REGN Current Assets figures stand at $18.2 billion (Q1 2026), $18.0 billion (Q4 2025), and $18.0 billion (Q3 2025).